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RESEARCH
The Plasmodium falciparum cytoplasmic 
translation apparatus: a promising therapeutic 
target not yet exploited by clinically approved 
anti-malarials
Christine Moore Sheridan1, Valentina E. Garcia1, Vida Ahyong1 and Joseph L. DeRisi1,2* 
Abstract 
Background: The continued spectre of resistance to existing anti-malarials necessitates the pursuit of novel targets 
and mechanisms of action for drug development. One class of promising targets consists of the 80S ribosome and 
its associated components comprising the parasite translational apparatus. Development of translation-targeting 
therapeutics requires a greater understanding of protein synthesis and its regulation in the malaria parasite. Research 
in this area has been limited by the lack of appropriate experimental methods, particularly a direct measure of parasite 
translation.
Methods: An in vitro method directly measuring translation in whole-cell extracts from the malaria parasite Plasmo-
dium falciparum, the PfIVT assay, and a historically-utilized indirect measure of translation, S35-radiolabel incorpora-
tion, were compared utilizing a large panel of known translation inhibitors as well as anti-malarial drugs.
Results: Here, an extensive pharmacologic assessment of the PfIVT assay is presented, using a wide range of known 
inhibitors demonstrating its utility for studying activity of both ribosomal and non-ribosomal elements directly 
involved in translation. Further, the superiority of this assay over a historically utilized indirect measure of translation, 
S35-radiolabel incorporation, is demonstrated. Additionally, the PfIVT assay is utilized to investigate a panel of clini-
cally approved anti-malarial drugs, many with unknown or unclear mechanisms of action, and show that none inhibit 
translation, reaffirming Plasmodium translation to be a viable alternative drug target. Within this set, mefloquine is 
unambiguously found to lack translation inhibition activity, despite having been recently mischaracterized as a ribo-
somal inhibitor.
Conclusions: This work exploits a direct and reproducible assay for measuring P. falciparum translation, demonstrat-
ing its value in the continued study of protein synthesis in malaria and its inhibition as a drug target.
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Background
Despite ongoing efforts in its treatment and preven-
tion, malaria remains a severe global health burden, with 
nearly half the world’s population at risk, and incidence 
of the disease actually increasing in the most recent 
years for which data are available [1]. Though malaria-
related mortality has continued to decrease, the rise in 
incidence is particularly concerning in light of reduced 
investment worldwide in combatting malaria, combined 
with climate change and geopolitical instability that may 
contribute to a resurgence of the disease [1]. One com-
pounding factor in the battle to eliminate malaria is the 
persistent emergence of drug resistance in the malaria 
parasite Plasmodium falciparum [1]. As combination 
therapies are the main defense against resistance, an 
important focus in therapeutic development is the iden-
tification of compounds with unique targets and novel 
mechanisms of action that are unlikely to be precluded 
by existing resistance mutations. Medicines for Malaria 
Venture (MMV) has recently demonstrated the potential 
of efforts directed at novel targets; two drugs currently 
showing great promise in clinical trials, SJ733 and cipar-
gamin, inhibit the P. falciparum cation ATPase PfATP4, 
constituting a new class of drug [2, 3].
One promising avenue for development of a novel tar-
get class is the inhibition of the P. falciparum ribosome, as 
well as other components of the translational machinery 
responsible for protein synthesis. Translation inhibitors 
have exhibited great clinical success as potent antibiotics, 
and in fact, several, including doxycycline and azithro-
mycin, have found additional application as anti-malari-
als, as they target ribosomes within the malaria parasite’s 
mitochondria and apicoplast, leading to loss of function 
of these organelles [4–6]. Interestingly, the P. falciparum 
cytoplasmic ribosome appears to occupy an evolutionary 
middle ground between prokaryotic and eukaryotic, dif-
ferentiating it sufficiently from human ribosomes to yield 
a useful therapeutic window [5]. Indeed, M5717 (previ-
ously DDD107498), a potent and highly selective inhibi-
tor of the 80S ribosome interacting protein P. falciparum 
eukaryotic elongation factor 2 (PfEF2), is currently in 
first-in-human study, validating the potential of the P. fal-
ciparum translational apparatus as an effective target for 
anti-malarial drugs of this class [7].
To facilitate the identification of translation inhibitors, 
a P. falciparum whole-cell extract-based in  vitro trans-
lation assay (PfIVT) was developed, and the technique 
successfully applied to detect small molecule inhibitors 
in the MMV Malaria Box [8]. More recently, it has been 
suggested that the widely used drug mefloquine may 
inhibit the 80S ribosome of P. falciparum [9]. In addition, 
many currently approved anti-malarial compounds lack 
a definitive mechanism of action, raising the possibility 
that some of these clinical therapies act through inhibi-
tion of translation. The aim of this study was to clarify 
which compounds truly exhibit inhibitory activity against 
the P. falciparum 80S ribosome and the associated trans-
lational apparatus. To do so, a panel of anti-malarial 
drugs (both clinical and pre-clinical) was compared with 
well-characterized inhibitors of translation and other 
defined control compounds in the PfIVT assay, as well 
as in the S35-radioabel incorporation assay, a historically 
utilized indirect measure of translation. Importantly, this 
demonstrated that none of the current clinical therapeu-
tics inhibit translation, including mefloquine. Regardless, 
testing of tool compounds shows that the PfIVT assay is 
capable of identifying not only translation inhibitors that 
directly interact with the ribosome, but also inhibitors 
of other non-ribosomal components of the translational 
machinery, demonstrating the broad utility of the assay 
for identifying novel malaria therapeutics that target P. 
falciparum translation.
Methods
Drug stocks
In vivo growth and in  vitro translation measurements 
were performed using the same drug dilutions. The 
anti-malarial drugs chloroquine, dihydroartemisinin, 
lumefantrine, monodesethyl amodiaquine, piperaquine, 
primaquine, and quinine were a generous gift from Dr. 
Phil Rosenthal of UCSF. SJ733 was generously provided 
by Dr. Kip Guy of St. Jude Children’s Research Hospital. 
All other compounds were purchased from the indicated 
vendors: DDD107498 (Apexbio #A8711-5), mefloquine 
hydrochloride (Sigma-Aldrich #M2319), emetine (Sigma-
Aldrich #E2375), cycloheximide (Fisher #AC35742-
0010), MMV008270 (Vitas-M Laboratory #STK591252), 
actinomycin D (Sigma-Aldrich #A1410), tubercidin 
(Sigma-Aldrich #T0642), thapsigargin (Sigma-Aldrich 
#SML1845), ionomycin (Sigma-Aldrich #407951), thios-
trepton (Sigma-Aldrich #598226), bruceantin (Toronto 
Research Chemicals #B689310), verrucarin A (Sigma-
Aldrich #V4877), anisomycin (Sigma-Aldrich #A5862), 
homoharringtonine (Sigma-Aldrich #SML1091), lac-
timidomycin (EMD Millipore #506291), nagilactone 
C (BOC Sciences #24338-53-2), suramin sodium salt 
(Sigma-Aldrich #S2671), puromycin (Thermo Fisher 
#A1113803), halofuginone (Sigma-Aldrich #32481).
Plasmodium falciparum strain and culturing
Plasmodium falciparum W2 (MRA-157) was obtained 
from MR4. Parasites were grown in human erythrocytes 
(2% haematocrit) in RPMIc (RPMI 1640 media supple-
mented with 0.25% Albumax II (GIBCO Life Technolo-
gies), 2  g/L sodium bicarbonate, 0.1  mM hypoxanthine, 
25  mM HEPES (pH 7.4), and 50  μg/L gentamicin), at 
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37 °C, 5%  O2, and 5%  CO2. Cells were synchronized with 
5% sorbitol treatment for two generations to achieve high 
synchronicity.
Growth inhibition assays
2μL of serial drug dilutions in 100% DMSO were dis-
pensed in triplicate to 96-well plates utilizing the LabCyte 
ECHO acoustic liquid handler. 198  µL of P. falciparum 
W2 cultures were added. Growth was initiated with ring-
stage parasites at 0.8% parasitaemia and 0.5% haemato-
crit. Plates were incubated at 37 °C, 5%  O2, and 5%  CO2 
for 72 h. Growth was terminated by fixation with 1% for-
maldehyde, and parasitized cells were stained with 50 nM 
YOYO-1 (Invitrogen). Parasitaemia was determined by 
flow cytometry on the BD LSRII, analysed using FlowJo 
software version 10, and EC50 curves were  plotted by 
GraphPad Prism. Two biological replicates were per-
formed for each drug.
Generation and quality control of extracts for Plasmodium 
falciparum in vitro translation assay
For PfIVT harvests, 1 L of synchronized parasite culture 
in 2–4% haematocrit was grown in two 500 mL HYPER-
Flask M vessels (Corning), and media was changed every 
8–12  h, with the final media change at 4–8  h prior to 
harvest. Parasites were harvested in the late trophozoite 
stage at 15–20% parasitaemia by centrifugation for 5 min 
at 1500×g at room temperature, followed by removal of 
media and addition of ice-cold 0.025–0.05% final sapo-
nin in Buffer A (20 mM HEPES pH 8.0, 2 mM Mg(OAc)2, 
120  mM KOAc). Due to variations between and within 
lots, saponin stocks were prepared in large volumes, 
aliquoted, and stored at − 20  °C. Percentage utilized 
for each batch of aliquots was determined empiri-
cally through pairwise testing of concentrations (1 for 
each HYPERFlask) and assessed via resulting activity of 
PfIVT extracts. Saponin-lysed pellets were centrifuged 
at 4 °C and 10,000×g for 10 min and washed twice with 
ice-cold Buffer A. Supernatant was carefully removed, 
and washed pellets were resuspended in an equal vol-
ume of Buffer B2 [20 mM HEPES pH8.0, 100 mM KOAc, 
0.75  mM  Mg(OAC)2, 2  mM DTT, 20% glycerol, 1X 
EDTA-free protease inhibitor cocktail (Roche)], flash fro-
zen, and stored in − 80  °C freezer until the sample was 
ready to homogenize.
Frozen pellets were thawed on ice and added to a 3-mL 
Luer lock syringe, which was then secured onto a pre-
chilled cell homogenizer containing a 4μm-clearance ball 
bearing (Isobiotec, Germany) that was pre-washed with 
ice-cold Buffer B2. Homogenate was passed between 
two syringes 20 times on ice, either by hand or by use of 
a custom robot built to accommodate the cell homog-
enizer [10]. Lysate was immediately centrifuged at 4  °C 
and 16,000×g for 10  min, and the supernatant (the 
resulting PfIVT extract) was transferred to a fresh tube, 
with a small (100 μL) aliquot set aside for activity testing. 
Extracts and test aliquots were flash-frozen and stored 
at − 80  °C. Test aliquots from multiple harvests were 
thawed on ice and tested in batches in the PfIVT assay 
(see below) across a small range of magnesium concen-
trations with a 2-h incubation time, using a firefly lucif-
erase reporter. Extracts that surpass the activity threshold 
of  104 relative luciferase units (RLU) were then thawed on 
ice and combined to generate large volume pools. Extract 
pools were flash-frozen in 200 μL aliquots and stored at 
− 80 °C. Extract pools were tested across a range of mag-
nesium concentrations via PfIVT assay to determine the 
optimum magnesium concentration. Once magnesium 
concentration has been determined, pools are then tested 
in the PfIVT assay in 15 min incubation time points up 
to 150 min to determine the kinetics of the extract pool, 
and thus the appropriate incubation time for the pool 
(~ 75–80% of maximum signal, within the linear range of 
the extract’s kinetic curve). Kinetics must be separately 
assessed for each reporter used (i.e. if a nanoluciferase 
reporter is used instead of firefly luciferase).
Magnesium concentration assays
Baseline magnesium levels of the PfIVT extracts were 
measured using a magnesium-dependent enzyme-based 
colorimetric assay kit (Sigma-Aldrich #MAK026). Two 
biological replicates of a dilution series of each extract 
were tested in duplicate with each of two separate kits, 
following the protocol provided with the kit. In brief, 
10 μL of each PfIVT extract (neat, or diluted 1:4 or 1:10 
with  ddH2O) added to 10 μL  ddH2O, along with a stand-
ard curve, was combined with 50 μL of master reaction 
mix (35  μL magnesium assay buffer, 10  μL developer, 
5 μL magnesium enzyme mix), and incubated for 10 min 
with shaking at 37  °C. 450  nm absorbance was read 
immediately after the initial incubation, and every 5 min 
thereafter on a Tecan plate reader until the highest A450 
approached (but did not exceed) 1.5× the initial reading. 
Values were fitted to, and interpolated from, the standard 
curve using Prism GraphPad.
Plasmodium falciparum in vitro translation assay
Plasmodium falciparum in  vitro translation (PfIVT) 
reactions were carried out in skirted v-bottom 96-well 
PCR plates (BioRad) and sealed with adhesive aluminum 
foil plate seals (Beckman Coulter, Indianapolis, IN, USA). 
200 nL of drug in 100% DMSO was dispensed in dupli-
cate to appropriate wells of the plate utilizing a Labcyte 
ECHO acoustic liquid handler. 19.8 μL of PfIVT reaction 
mix (per 20 μL: 14 μL extract, 1 μg T7-transcribed fire-
fly luciferase mRNA, 10 µM amino acid mixture, 20 mM 
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HEPES/KOH pH 8.0, 75 mM KOAc, 2 mM DTT, 0.5 mM 
ATP, 0.1 mM GTP, 20 mM creatine phosphate, 0.2 μg/μL 
creatine kinase, and the appropriate amount of Mg(OAc)2 
as determined for the particular pool of extract) was then 
dispensed to each well using Rainin E4 12-channel elec-
tronic pipettes (Rainin Instruments, Oakland, CA, USA). 
Reactions were incubated at 37  °C for the appropriate 
amount of time as determined for the particular pool 
of extract. After incubation, the reactions were placed 
on ice, then quenched through transfer to a 96-well 
LUMITRAC 200 flat-bottom white assay plate (Greiner 
Bio-One, Monroe, NC, USA) containing 2 μL of 50 μM 
cycloheximide (dispensed using the Labcyte ECHO), 
then immediately centrifuged to combine the PfIVT 
reaction with the cycloheximide for a final concentration 
of 5  µM cycloheximide. Reactions were assayed using 
the Promega GloMax-Multi + microplate reader with a 
three-second delay and three-second integration after 
addition of 200 μL luciferin reagent dispensed at a speed 
of 200  μL/second (firefly luciferin reagent: 20  mM Tri-
cine, 2.67 mM MgSO4 × 7H2O, 0.1 mM EDTA, 33.3 mM 
DTT, 530 μM ATP, 270 μM Acetyl CoEnzyme A, 1 mM 
d-Luciferin, 265  μM Magnesium Carbonate Hydroxide, 
pH 8.15). Three biological replicates were performed 
in duplicate for each drug.  IC50 curves were plotted by 
GraphPad Prism.
Rabbit reticulocyte in vitro translation assay
Rabbit reticulocyte in  vitro translation assays were per-
formed as described in Ahyong et al. [8] with the excep-
tion that the final [DMSO] for MMV008270 was 2.5% 
and all other final [DMSO] = 0.55%  IC50 curves were 
plotted by GraphPad Prism.
S35 incorporation assay
Parasite purification
Synchronized parasites were cultured in 2% haemato-
crit at 10–15% parasitaemia, and MACS purified at the 
late trophozoite stage to remove uninfected erythrocytes 
using standard protocols. In brief, at least two LD MACS 
Separation columns (Miltenyi Biotech) per 50 mL of cul-
ture were washed with 1.25  mL of pre-warmed RPMIc. 
Next, cultures were added to the columns 5 mL at a time 
and allowed to gravity filter at 37 °C. Finally, the columns 
were rinsed with 2.5 mL of pre-warmed RPMIc, removed 
from the magnetic stand, and eluted with 2  mL of pre-
warmed RPMIc.
Drug treatment and S35 labelling
1 μL of drug in 100% DMSO was dispensed to each well 
of a 96-well round-bottom culture plate utilizing the 
Labcyte ECHO acoustic liquid handler. 2 × 107 MACS-
purified parasites in 199  μL of RPMIc were then added 
to each well. Parasites were incubated with drug for 2 h 
at 37 °C, 5%  CO2, 5%  O2. Next, samples were transferred 
from 96-well plates to 1.5 mL screw-cap microfuge tubes. 
35  μCi of EasyTag™ Express S35 Protein Labeling Mix 
(Perkin Elmer) diluted to 10  μL with RPMIc was added 
to each tube. Reactions were incubated at 37 °C with mild 
shaking for 2 h.
Washing and lysis
After incubation, cells were pelleted and 160 μL of super-
natant was removed. Parasites were then washed with 
200 μL of ice-cold PBS containing 50 μM cycloheximide 
four times. After the final wash, all supernatant was 
removed and samples were resuspended in 15 μL of 2X 
SDS buffer (100 mM Tris–Cl pH 6.8, 4% SDS, 20% glyc-
erol, 0.1 M DTT). Samples were boiled at 98 °C for 5 min 
and stored at − 20 °C.
Scintillation counting
Samples were thawed at room temperature, boiled for 
5  min at 98  °C, and spun at max speed in a tabletop 
microcentrifuge for 10  min. 10  μL of supernatant per 
sample was placed on a 0.45μm nitrocellulose mem-
brane (HAWP02400 from Millipore). Each membrane 
was washed 4 times with 15 mL of TBS-T then placed in 
a 20  mL HDPE scintillation vial (Fisher Scientific) with 
8  mL of Ecoscint A (National Diagnostics). S35 counts 
were measured for 1 min using a Beckmann coulter, LS 
6500 Multi-purpose Scintillation Counter. Three biologi-
cal replicates were performed for each drug.
Mefloquine solubility assay
PfIVT extracts were incubated with a dilution series of 
mefloquine or DMSO control for 90 min. All PfIVT con-
ditions were the same as above, except without addition 
of cycloheximide to stop translation. Reactions were cen-
trifuged at 16,100×g for 10  min at room temperature; 
resulting supernatant was then filtered and added to cul-
tures for the P. falciparum growth inhibition assays as 
described above.
Results
Extract optimization and quality control 
for the Plasmodium falciparum in vitro translation assay
To ensure reproducible consistency and robustness of the 
P. falciparum in vitro translation (PfIVT) assay, extensive 
validation of parasite extracts was performed. A detailed, 
step-by-step protocol is presented in the Additional files 
1, 2, 3, 4 and 5. Only those extracts surpassing a rigor-
ous activity threshold were utilized for the PfIVT assay, 
and extracts from individual harvests meeting this crite-
rion were combined to generate large pools for use across 
many assays. Ribosome activity is especially sensitive to 
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divalent cations, in particular magnesium concentration 
[11]. Therefore, the magnesium concentration of each 
PfIVT extract was  measured, followed by determina-
tion of  the optimal amount of magnesium required by 
each extract in order to achieve maximal activity. Post-
harvest magnesium concentrations were typically less 
than 2 mM, whereas the maximum translational activity 
corresponded to a final PfIVT reaction concentration of 
approximately 4 mM magnesium (Fig. 1a, b). Upon deter-
mining optimal magnesium conditions for each pool of 
extract, kinetic curves were generated with 15-min incre-
ments to establish the ideal incubation time for the assay 
(Fig.  1c). This was necessary, since assay kinetics varied 
between extracts. Note that separate kinetic curves must 
also be established for the particular reporter utilized (in 
this case, firefly luciferase). To maintain maximal sensi-
tivity to inhibitors and linearity of the assay, PfIVT exper-
iments were conducted at the time point corresponding 
to 75–80% of the saturation signal (Fig. 1c).
Probing different stages of translation in a Plasmodium 
falciparum cellular extract system using tool compounds
The process of translation may be binned into three 
main stages: initiation, elongation, and termination [12, 
13]. In eukaryotes, this process is carried out by the 80S 
ribosome, comprised of a small (40S) and large (60S) 
subunit [12, 13]. To further validate the PfIVT assay and 
investigate its capacity to interrogate the entirety of the 
normal activity of the 80S ribosome (and thus identify 
drugs inhibiting all steps of the process of translation), an 
extensive panel of previously characterized translational 
inhibitors was tested, both in the PfIVT assay, as well 
as in the historically utilized S35-radiolabelled amino 
acid incorporation assay. In contrast to the PfIVT assay, 
which directly measures activity of the 80S ribosome 
and the associated translational apparatus, S35 incor-
poration is an indirect measure of translation, and, as 
such, is affected by upstream and parallel pathways not 
directly involved in ribosomal activity. For instance, the 
S35 incorporation assay is impacted by changes in cell 
viability, stress or other responses that alter proteosta-
sis, and even changes to cellular import mechanisms or 
integrity of the parasite membrane, as the assay requires 
exogenous addition of radiolabelled amino acid. Despite 
the resulting ambiguity and often misleading nature of 
results generated, S35 incorporation has remained a 
commonly used assay for studying parasite translation in 
the absence of a better alternative [9].
Commercially available compounds that directly inter-
act with the eukaryotic ribosome to inhibit translation 
initiation and/or elongation via a variety of mechanisms 
and binding sites, as well as several inhibitors of transla-
tion known to act upon non-ribosomal components of 
the translational machinery were tested (Tables  1 and 
2). The eukaryote-specific inhibitors bruceantin and 
verrucarin A inhibit translation initiation by blocking 
initial peptide-bond formation through binding of mutu-
ally exclusive sites (with bruceantin binding the A-site 
and verrucarin binding between the P- and A-sites) 
[13–17]. Suramin, also a specific inhibitor of the eukar-
yotic ribosome, inhibits both initiation and elongation 
through binding of multiple sites on the 40S, 60S and 80S 
a
b
c
Fig. 1 Optimization and quality control parameters of PfIVT extracts. 
a Translational activity of 3 representative extracts (X, Y, and Z) 
over a range of reaction magnesium concentrations. b Measured 
basal extract magnesium concentration (blue bars) and optimum 
translation reaction magnesium concentration (red bars) for each 
of 3 representative PfIVT extracts (X, Y, and Z). c Kinetic curves for 
translational activity of each of 3 representative PfIVT extracts (X, Y, 
and Z) at the optimum reaction magnesium concentration shown 
in part B. Arrows indicate the timepoint to use for inhibition assays 
in the extracts meeting the activity threshold, indicating ~ 75% of 
saturation signal. The dashed line at  104 relative luciferase units (RLU) 
represents the cutoff for acceptable translational activity for the assay. 
Extract X does not consistently meet the  104 RLU activity threshold 
and would not be used for PfIVT assays
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ribosomes [18]. The eukaryote-specific elongation inhibi-
tors tested are also distinct in their activities: cyclohex-
imide and lactimidomycin overlap in their binding of the 
ribosome A-site, but differences in size and side-chains 
yield unique effects; anisomycin also overlaps cyclohex-
imide’s binding site, but the two drugs bind the ribosome 
in distinct rotational conformations at different steps of 
elongation; homoharringtonine binds the A-site, but 
specifically inhibits re-initiating ribosomes; and nagi-
lactone C inhibits both eEF-1α-dependent aminoacyl-
tRNA loading and peptidyl transferase activity [13, 14, 
19–21]. Halofuginone, also a specific inhibitor of eukary-
ote translation, does not interact with the ribosome, but 
instead inhibits glutamyl-prolyl-tRNA synthetase [22]. 
Puromycin was the sole pan-inhibitor tested, and acts 
as a tRNA mimetic that is incorporated into the nascent 
polypeptide chain, leading to its premature termination 
[23, 24]. Negative controls were thiostrepton, a specific 
inhibitor of prokaryotic translation initiation and elon-
gation; actinomycin D, an inhibitor of RNA polymerase 
II; tubercidin, an adenosine mimetic; and thapsigargin, a 
sarco/endoplasmic reticulum ATPase (SERCA) inhibitor 
[25–34]. 
After determining the EC50 of each drug for the P. falci-
parum W2 strain in a 72-h parasite growth assay, the drugs 
were characterized in both the S35 incorporation and 
PfIVT assays (Table 3) (Figs. 2 and 3). Drugs were tested in 
the S35 and PfIVT assays at 0.1-, 1-, 10-, and 100-fold their 
determined growth assay EC50 in W2 parasites, except in 
cases where the highest concentration was constrained by 
solubility or available stock solution. The translation ini-
tiation inhibitors bruceantin and verrucarin A were both 
potent (nanomolar) inhibitors of S35 incorporation and 
PfIVT (Fig. 2). All translation elongation inhibitors (aniso-
mycin, cycloheximide, homoharringtonine, lactimidomy-
cin, and nagilactone C) also strongly inhibited both S35 
incorporation and PfIVT (Fig. 2). Cycloheximide was addi-
tionally tested at 1000-fold its EC50, as it did not inhibit 
S35 incorporation at the lower concentrations tested, but 
did at this higher concentration, in line with inhibitory 
concentrations in recent reports, which also show that 
significantly higher concentrations of cycloheximide are 
required for complete, measurable inhibition of translation 
than for rapid and total parasite killing in vivo (Additional 
file 6) [8, 9, 35]. Suramin, which has been shown to inhibit 
both translation initiation and elongation, robustly inhib-
ited PfIVT, but not S35 incorporation, likely due to poor 
cell permeability and the short timeframe of the S35 assay 
(2-h drug pre-incubation followed by 2-h radiolabel incor-
poration) (Fig.  2). The tRNA mimetic puromycin, which 
induces premature termination of nascent polypeptides, 
inhibited both S35 incorporation and PfIVT with similar 
efficacy (Fig. 2). Elucidating an even greater range of utility 
for the PfIVT assay, it was shown to be capable of identify-
ing inhibitors of non-ribosomal components of translation. 
The glutamyl-prolyl-tRNA synthetase inhibitor halofugi-
none inhibits both S35 incorporation and the PfIVT assay 
(Fig. 2). In sum, these data demonstrate the ability of the 
PfIVT assay to interrogate both direct ribosomal activity, 
as well as extra-ribosomal components of the translational 
machinery.
Table 1 Mechanism of action and species specificity of translation inhibitors
Compound Specificity Mechanism of action References
Bruceantin Eukaryotic (Pf cytoplasmic ribosomes) Inhibits initiation [16, 17]  
Verrucarin A Eukaryotic (Pf cytoplasmic ribosomes) Inhibits initiation, binds between P- & A- sites [13–15]  
Suramin Eukaryotic (Pf cytoplasmic ribosomes) Inhibits initation & elongation, multiple binding sites [18]  
Anisomycin Eukaryotic (Pf cytoplasmic ribosomes) Inhibits elongation, binds A-site [13, 17]
Cycloheximide Eukaryotic (Pf cytoplasmic ribosomes) Inhibits elongation, binds E-site [13]
Homoharringtonine Eukaryotic (Pf cytoplasmic ribosomes) Inhibits elongation on re-initiating ribosomes, binds A-site [13, 20]
Lactimidomycin Eukaryotic (Pf cytoplasmic ribosomes) Inhibits elongation, binds E-site [13]
Nagilactone C Eukaryotic (Pf cytoplasmic ribosomes) Inhibits elongation, binds A-site [13, 21]
Puromycin Pan-inhibitor tRNA mimetic [23, 24]
Halofuginone Eukaryotic Inhibits glutamyl-prolyl-tRNA synthetase [22]
Thiostrepton Prokaryotic (Pf mitochondrial & apicoplast 
ribosomes)
Inhibits initiation & elongation [25– 31]
Table 2 Mechanism of action of non-translation inhibitors
Compound Mechanism of action References
Actinomycin D RNA polymerase II inhibitor [32]
Tubercidin Adenosine mimetic [33]
Thapsigargin SERCA inhibitor [34, 39, 40]
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The Plasmodium falciparum in vitro translation assay 
measures activity of cytoplasmic ribosomes
Importantly, all of the eukaryotic ribosome-specific 
inhibitors, which therefore should inhibit only P. falci-
parum cytoplasmic and not apicoplast or mitochondrial 
ribosomes, displayed inhibition in the PfIVT assay, with 
several achieving complete or near complete blocking of 
translation (suramin, anisomycin, lactimidomycin, nagi-
lactone C) (Fig. 2). In addition, the prokaryotic ribosome-
specific inhibitor thiostrepton did not inhibit the PfIVT 
assay at any concentration tested, despite inhibiting the 
S35 assay at concentrations above its determined EC50 
(Fig.  3). Thiostrepton is known to have multiple targets 
apart from ribosomes in eukaryotes and has been shown 
to induce an ER stress response with a phenotype simi-
lar to thapsigargin, which likely accounts for its activity in 
the S35 assay [36–38].
The S35 incorporation assay is not a reliable indicator 
of direct translation inhibition
Although it is well documented in other model systems 
(i.e. yeast) that the S35-radiolabelled amino acid incor-
poration assay is an indirect measure of translation and 
can, as such, generate many misleading artifacts, this 
has not yet been characterized carefully with respect to 
Plasmodium spp. [39, 40]. Despite this, several studies in 
Plasmodium have relied on this indirect measure as a pri-
mary readout of translation [9, 41]. To address this and 
further determine the specificity of the PfIVT assay rela-
tive to the S35 uptake assay, a panel of small molecules 
that are known to inhibit cellular processes other than 
translation were tested (Tables 2 and 3). Not surprisingly, 
actinomycin D, an inhibitor of transcription targeting 
RNA Polymerase II, and the SERCA inhibitor thapsigar-
gin both exhibited strong inhibition in the S35 incorpora-
tion assay, but had no effect in the PfIVT assay (Fig. 3). 
Tubercidin, an adenosine mimetic, had a modest inhibi-
tory effect on S35 incorporation, but, again, negligible 
effect in the PfIVT assay (Fig. 3). These data confirm that 
the PfIVT assay directly measures translation, and high-
light the lack of translation specificity of the S35 incorpo-
ration assay.
Analysis of clinically‑approved anti‑malarials reveals 
that none, including mefloquine, inhibit the 80S ribosome
Next, a panel of clinically approved anti-malarial drugs 
with undefined or disputed mechanisms of action was 
tested, to determine whether any might act through 
direct inhibition of translation, subjecting these drugs 
to the same battery of assays described above (P. falcipa-
rum growth, PfIVT, and S-35 incorporation) (Table  3). 
Chloroquine and piperaquine were mild inhibitors of the 
S35 incorporation assay at the highest drug concentra-
tions tested (Fig. 4). Quinine, lumefantrine, primaquine, 
monodesethyl amodiaquine (the active metabolite of 
amodiaquine), and dihydroartemisinin were moder-
ate-to-strong inhibitors of the S35 incorporation assay 
(Fig.  4). SJ733, an inhibitor of the sodium transporter 
PfATP4, and a clinical candidate currently in Phase I tri-
als, exhibited strong inhibition in the S35 incorporation 
assay (Fig. 4). Notably, none of these anti-malarial drugs 
inhibited the PfIVT assay. However, primaquine cannot 
Table 3 Half-maximal effective concentrations (nM) determined in P. falciparum growth inhibition assay
a  Active metabolite of amodiaquine
Test compounds 72H growth inhibition EC50 (nM) Antimalarials 72H growth 
inhibition EC50 
(nM)
Bruceantin 4.2 MMV008270 2400
Verrucarin A 0.6 SJ733 60
Suramin 1819 M5717 (DDD107498) 1
Anisomycin 39 Quinine 370
Cycloheximide 0.6 Chloroquine 333
Homoharringtonine 6.8 Mefloquine 25
Lactimidomycin 22 Piperaquine 26
Nagilactone C 1310 Primaquine 1849
Puromycin 52 Monodesethyl  amodiaquinea 61
Halofuginone  2 Lumefantrine 4
Thiostrepton 942 Dihydroartemisinin 3
Actinomycin D 10
Tubercidin 168
Thapsigargin 2900
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be ruled out with complete certainty as an inhibitor of 
translation, as its active metabolite may not be produced 
in an in vitro setting, and it does show moderate activity 
in the S35 incorporation assay [42].
Also included were several drugs (clinical and pre-
clinical) that have recently been reported to inhibit trans-
lation (Table  3) [7–9]. MMV008270 was a moderate 
inhibitor of the S35 incorporation assay, while meflo-
quine and DDD107498 robustly inhibited S35 incor-
poration (Fig.  4). Strikingly, while DDD107498 and 
MMV008270 inhibited the PfIVT assay, mefloquine 
failed to do so (Fig.  4). Interestingly, MMV008270 was 
an exceptionally effective inhibitor of translation in the 
PfIVT assay at all concentrations tested (Fig.  4). These 
Fig. 2 Dose-dependent inhibition of S35 incorporation and PfIVT assays by eukaryotic translation inhibitors. Dose-dependent inhibition, calculated 
as  % inhibition, of S35 incorporation (blue bars) and PfIVT assays (red bars). Name of compound, mechanism of action, and molecular structure are 
displayed at top of each graph. Compounds were tested at 0.1-, 1-, 10-, and 100-fold the EC50 calculated in in vivo growth inhibition assay, except 
where upper concentration was limited by solubility, indicated by *
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data reveal that mefloquine has recently been mischar-
acterized as a ribosome inhibitor through use of the S35 
incorporation assay, when it does not, in fact, directly 
inhibit translation [9].
To further validate the PfIVT data regarding meflo-
quine, the PfIVT assay was repeated, alongside a com-
mercially available rabbit reticulocyte in vitro translation 
assay (RRIVT), with a full titration of drug to determine 
half maximal effective values for both mefloquine and 
DDD107498 (Fig.  5). As expected, the positive control 
cycloheximide was a robust inhibitor of both translation 
systems (PfIVT IC50: 31.91 nM, RRIVT IC50: 37.8 nM), 
while DDD107498 was a potent inhibitor of P. falcipa-
rum, but not rabbit reticulocyte translation, confirming 
the reported high P. falciparum selectivity of DDD107498 
(PfIVT IC50: 60.5  nM) (Fig.  5). In contrast, mefloquine 
failed to inhibit in either the PfIVT or RRIVT assay, even 
at concentrations as high as 20 μM (Fig. 5). The reported 
binding site of mefloquine to the 80S ribosome is on the 
highly conserved ribosomal protein uL13; if this were 
indeed the active binding site of the drug, mefloquine 
should inhibit the RRIVT assay [43]. To rule out the pos-
sibility that mefloquine solubility may be a confound-
ing factor in the IVT assays, completed PfIVT reactions 
with a dilution series of mefloquine or DMSO control 
were centrifuged at high speed, sterile-filtered, and the 
resulting supernatant was used as the input for an in vivo 
growth assay. EC50 values were comparable between 
the IVT reaction supernatant containing mefloquine 
(12.31  nM) and mefloquine alone (4.17  nM), thus dem-
onstrating that mefloquine is soluble in the PfIVT assay 
(Additional file 7). These data make clear that mefloquine 
does not act through inhibition of the P. falciparum ribo-
some, nor through other direct inhibition of the transla-
tional machinery.
Discussion
This work presents an extensive dissection and valida-
tion of the whole-cell extract-derived PfIVT assay, the 
only reported direct measure of P. falciparum translation 
to date. Through probing the assay with numerous small 
molecule inhibitors of translation, exhibiting a diversity 
of binding sites and mechanisms of action, as well as a 
variety of well-characterized tool compounds inhibiting 
non-translational pathways, it is demonstrated that the 
PfIVT assay specifically measures P. falciparum cyto-
plasmic ribosome activity. In  vitro translation extracts 
are inherently difficult to make, and even more so for an 
intraerythrocytic parasite. However, when subjected to 
stringent quality control and careful optimization, the 
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Fig. 3 Dose-dependent inhibition of S35 incorporation and PfIVT assays by negative control compounds. Dose-dependent inhibition, calculated 
as  % inhibition, of S35 incorporation (blue bars) and PfIVT assays (red bars) by negative control compounds: prokaryotic translation inhibitor and 
inhibitors of other (non-translation) cellular processes. Name of compound, mechanism of action, and molecular structure are displayed at top of 
each graph. Compounds were tested at 0.1-, 1-, 10-, and 100-fold the calculated EC50 calculated in in vivo growth inhibition assay, except where 
upper concentration was limited by solubility, indicated by *
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PfIVT assay reliably and specifically identifies inhibitors 
of translation initiation and elongation, as well as inhibi-
tors of non-ribosomal proteins necessary for translation, 
such as tRNA synthetase.
The PfIVT assay is particularly valuable to the study 
of P. falciparum translation as a direct measure of 
translation, as opposed to the indirect measures to 
which the field has historically been constrained, such 
as incorporation of radiolabelled amino acids in  vivo. 
Importantly, these data show the PfIVT assay is signifi-
cantly more specific, and in some cases more sensitive, 
than S35-radiolabel incorporation in identifying small 
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Fig. 4 Dose-dependent inhibition of S35 incorporation and PfIVT assays by antimalarial compounds. Dose-dependent inhibition, calculated as  % 
inhibition, of S35 incorporation (blue bars) and PfIVT assays (red bars) by pre-clinical and clinically-approved antimalarial compounds. Name of 
compound, mechanism of action (where definitively known), and molecular structure are displayed at top of each graph. Compounds were tested 
at 0.1-, 1-, 10-, and 100-fold the calculated EC50 calculated in in vivo growth inhibition assay, except where upper concentration was limited by 
solubility, indicated by *
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molecule inhibitors of translation. Indeed, the PfIVT 
assay specifically identified all eukaryotic translation 
inhibitors tested, while S35-radiolabel incorporation was 
prone to false-positives. This work shows that none of 
the clinically approved anti-malarials tested are inhibi-
tors of translation, emphasizing the potential for trans-
lation as a useful therapeutic target, as there is unlikely 
to be pre-existing mechanism-specific resistance to any 
identified candidates resulting from use of these drugs. 
It is notable that mefloquine, in contrast to other previ-
ously reported translation inhibitors, did not exhibit any 
inhibitory activity. Mefloquine was likely mischaracter-
ized as an 80S ribosome inhibitor through a combination 
of non-specific inhibition of S35 incorporation, as well as 
artifacts arising from cryo-EM structures obtained under 
the non-physiologic condition of 10  mM magnesium—
well above the ~ 4  mM magnesium found herein to be 
optimal for translation, as well as the physiologic mag-
nesium concentrations noted in other eukaryotes and E. 
coli (Fig. 1) [9, 44–46].
While the PfIVT assay exhibits clear benefits over 
existing methodologies for the study of P. falciparum 
translation, it is acknowledged that the technique has 
several limitations. As is the case with in  vitro trans-
lation systems in other organisms, the current assay is 
likely biased toward the study of non-cap-dependent 
initiation and elongation. Uncapped mRNA were uti-
lized in this study to focus specifically on activity of 
the 80S ribosome itself, rather than the cap-recogni-
tion apparatus. It is possible that utilization of capped 
mRNA in future studies would facilitate interroga-
tion of cap-dependent translation initiation. Likewise, 
there are few characterized pharmacologic inhibitors 
of eukaryotic translation termination, none of which 
are currently commercially available; thus, the PfIVT 
system, as described, may not be sensitive to all spe-
cific inhibitors of translation termination. Additionally, 
some translation inhibitors, such as homoharringto-
nine, demonstrated greater potency in the S35 incorpo-
ration and growth inhibition assays than in PfIVT. Such 
variation between the two assays may suggest off-target 
a b
c
Fig. 5 Dose-response curves of Pf growth, PfIVT, and RRIVT for mefloquine and controls. Dose-response curves comparing inhibition, calculated 
as % inhibition, of P. falciparum growth assay (black), P. falciparum in vitro translation assay (red), and commercially available rabbit reticulocyte 
in vitro translation assay (purple) for a cycloheximide, b DDD107498 (M5717), and c mefloquine. Name of compound, mechanism of action (where 
definitively known), and molecular structure are displayed at top of each graph
Page 12 of 13Sheridan et al. Malar J          (2018) 17:465 
effects of these drugs, or differences between whole liv-
ing cells and cellular extracts.
Conclusions
Determining the true molecular targets of anti-malarials 
is critical to improved therapeutic development. Exploit-
ing differences between P. falciparum and mammalian 
ribosomes remains a promising avenue, as evidenced by 
the potent and discriminating drug DDD107498. Here, 
it is shown that orthogonal biochemical assays may be 
used to test hypotheses generated by structural data and 
cell-based assessments. This investigation of mefloquine 
reaffirms that direct functional measurements of drug 
activity are critical to identifying the genuine molecular 
targets of drugs. Importantly, this work demonstrates 
that the PfIVT assay is a uniquely direct measure of P. fal-
ciparum translation that can be used to facilitate a bet-
ter understanding of the specifics of P. falciparum protein 
synthesis, with potentially great consequences for anti-
malarial therapeutic development.
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